Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)
Funds the collaborative development and validation of a patient-centered decision-making tool to improve care and outcomes for those with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
Funder: Pfizer Inc.
Due Dates: June 3, 2026 (Submission deadline, full application)
Funding Amounts: Up to $250,000 USD for one project; maximum project length is 1 year; includes direct, indirect, and overhead costs (capped at 28%).
Summary: Supports the collaborative development, validation, and evaluation of a shared decision-making tool to improve health outcomes for patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
Description
This grant opportunity funds the creation, validation, and evaluation of a shared decision-making tool (decision aid) to enhance patient-centered care for individuals with Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The initiative aims to address gaps and challenges in the ATTR-CM care pathway by supporting projects that engage medical societies or professional organizations, in partnership with patient advocacy groups, to co-develop a tool grounded in decision-making theory and informed by stakeholder input. The tool should improve decision quality, health outcomes, patient experience, and quality of care, and must undergo rigorous usability and validation testing to ensure practical clinical utility.
